According to the contract research organization (CRO), the acquisition – commercial details of which were not disclosed – is part of the company’s strategy to provide end-to-end R&D services.
Dr. Boliang Lou, chairman and CEO of Pharmaron commented in the company’s press release: “The addition of Xceleron develops and differentiates our capabilities in translational science and clinical development services, and further strengthens our ability to support our worldwide collaborators and partners with fully integrated pharmaceutical R&D services.”
According to the company, Xceleron’s microtracer use and Accelerator Mass Spectrometry (AMS) technology complement Pharmaron’s radiolabeled compound manufacturing and radiolabeled metabolism platforms, which are operated in the UK.
The AMS platform allows for the identification and analysis of therapeutically and biologically relevant entities and supports novel biomarker discovery.
Pharmaron is not providing any additional comment at this time.
As Outsourcing-Pharma.com previously reported, Pharmaron acquired MSD's Hoddesdon, UK-based Good Manufacturing Practice (GMP) standard facilities to advance its API formulation development in September of last year.
As the CRO told us at the time, the deal was expected to close in Q1 2017.
Per the agreement, Pharmaron will occupy research buildings previously owned by MSD (Merck in the US and Canada), while MSD will continue to use the site as its headquarters, leasing the site's main office buildings.